RE: Rns, institution increases holdings20 Jun 2018 08:30
I think if HVO had not indicated that they have no intentions of taking FLU V through phase three themselves I would never have bought shares here. As that would bring into the market mind enormous placings etc to fund it.
But as it stands there is very little downsides here in the short to mid term. They will license the phase three mass trial out, getting a huge boost to the share price within the next couple of months.
If the trial is a failure (very unlikely) then longer term that is a risk. But from this point long term the risk/reward is massively in favour of reward.